The use of MCP-1 and soluble CD40 ligand in a pathophysiology-guided approach to the management of coronary artery disease.
The management of coronary artery disease has become increasingly complex as additional factors are identified that play a role in the underlying pathophysiology of the disease and as the number of available therapies expands. Cardiac biomarkers play an increasingly important clinical role, and demonstrate value as tools to facilitate diagnosis, risk stratification and possibly to guide therapy. Monocyte chemoattractant protein-1 and soluble CD40 ligand are strongly implicated in the pathophysiology of coronary artery disease, from plaque formation to plaque rupture and thrombosis, and the measurement of these biomarkers has demonstrated promise in preliminary studies. Further investigation of these and other emerging biomarkers may offer further insight into the pathogenesis of coronary artery disease and its complications, may help to identify possible targets for future therapy, and lead to simple tests that are useful in clinical medicine.